OREGON/HAWAII NODE

OREGON/HAWAII NODE
(now Western States Node, 2010 - )

Dennis McCarty, Ph.D. [email]
Principal Investigator
Department of Public Health and Preventive Medicine
Oregon Health and Science University

Find Node Publications

The Oregon/Hawaii Node (formerly the "Oregon Node") joined the Clinical Trials Network in September 1999 and was renewed in 2005. It included sites in Oregon, Hawaii, and Washington. These programs serve a growing number of Latino, Native American, Hawaiian, Russian, Asian, and female clients. Services are provided across the treatment continuum.

The Oregon/Hawaii Node combined with the California/Arizona Node in 2010 to form the Western States Node.


OREGON/HAWAII NODE PROTOCOL INVOLVEMENT

CTN-0002 Buprenorphine/Naloxone versus Clonidine for Outpatient Opiate Detoxification
CTN-0003 Suboxone (Buprenorphine/Naloxone) Taper: A Comparison of Taper Schedules
CTN-0005 MI (Motivational Interviewing) to Improve Treatment Engagement and Outcome in Subjects Seeking Treatment for Substance Abuse
CTN-0008 Assessment of the National Drug Abuse Clinical Trials Network: A Baseline for Investigating Diffusion of Innovation
CTN-0012 Characteristics of Screening, Evaluation, and Treatment of HIV/AIDS, Hepatitis C Viral Infections, and Sexually Transmitted Infections in Substance Abuse Treatment Programs
CTN-0017 HIV and HCV Intervention in Drug Treatment Settings
CTN-0020 Job Seekers Training for Patients with Drug Dependence
CTN-0021 Motivational Enhancement Treatment to Improve Treatment Engagement and Outcome for Spanish-Speaking Individuals Seeking Treatment for Substance Abuse
CTN-0027 Starting Treatment with Agonist Replacement Therapies (START)
CTN-0027-A-1 START Pharmacogenetics: Exploratory Genetic Studies in Starting Treatment with Agonist Replacement Therapies
CTN-0029 Attention Deficit Hyperactivity Disorder (ADHD) in Adult Smokers
CTN-0030

Prescription Opioid Addiction Treatment Study (POATS)

CTN-0030-A-1 Collection of Economic Data for the Prescription Opioid Addiction Treatment Study
CTN-0031 Stimulant Abuser Groups to Engage in 12-Step (STAGE-12): Evaluation of a Combined Individual-Group Intervention to Reduce Stimulant and Other Drug Use by Increasing 12-Step Involvement
CTN-0031-A-1 An Evaluation of Neurocognitive Function, Oxidative Damage, and Their Association with Treatment Outcomes in Methamphetamine and Cocaine Abusers
CTN-0031-A-3 Organizational and Practitioner Influences on Implementation of STAGE-12
CTN-0032 HIV Rapid Testing and Counseling
CTN-0032-A-1 Economic Analysis of HIV Rapid Testing in Drug Abuse Treatment Programs
CTN-0033-Ot-1 Methamphetamine Use Among American Indians
CTN-0033-Ot-5 The Choctaw Nation Methamphetamine Data Needs Project
CTN-0038-Ot Barriers to Substance Abuse Treatment Among Asian Americans and Pacific Islanders
CTN-0044 Web-Delivery of Evidence-Based, Psychosocial Treatment for Substance Use Disorders
CTN-0044-A-2 Acceptability of a Web-delivered, Evidence-based, Psychosocial Intervention among Individuals with Substance Use Disorders who Identify as American Indian/Alaska Native
CTN-0046 Smoking Cessation and Stimulant Treatment (S-CAST): Evaluation of the Impact of Concurrent Outpatient Smoking Cessation and Stimulant Treatment on Stimulant Dependence

 



Supported by a grant from the National Institute on Drug Abuse to the University of Washington Alcohol and Drug Abuse Institute.
The materials on this site have neither been created nor reviewed by NIDA.
Updated 10/2011 -- http://ctndisseminationlibrary.org/nodes/ornode.htm
info@ctndisseminationlibrary.org